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AIM: To evaluate and compare the patients opinion on the two types of anti- 
TNF-α therapies in a Hungarian cohort of IBD patients. METHODS: This 
was a prospective, multicentre, questionnaire-based observational study car-
ried out in three Hungarian tertiary centres. From April to September 2014, 
an anonymous questionnaire was distributed to patients diagnosed with ul-
cerative colitis (UC) or Crohn’s disease (CD), who have received infliximab 
(IFX) and/or adalimumab (ADA). The survey focused on the preferences of 
the two anti-TNF-α therapies on the basis of the efficacy, the administration 
routes and the side-effects. RESULTS: 292 IBD patients, 216 CD, 75 UC and 1 
indeterminate colitis patient completed the questionnaire. The mean duration 
of biological therapy was 1.7 (1 - 7) years. IFX treated patients noticed im-
provement of symptoms at 4 - 5 weeks while ADA treated patients noticed at 
5 - 6 weeks. There was no difference between the patients’ satisfaction re-
garding the types of anti-TNF-α therapy if they received both. However, sub-
cutaneous administration was preferred by ADA-treated patients previously 
receiving IFX (p = 0.007) compared to intravenous route and they did not in-
tend to change the mode of therapy (p = 0.040). 90% of the patients, receiving 
only IFX or ADA were satisfied with their present therapy. The majority of 
patients (186/292, 63.7%) would not switch therapy. 63 of 291, 22% of the pa-
tients reported to have some concern with biological therapy—the majority 
(32/63, 50.8%) due to fear from side effects. CONCLUSION: Generally, pa-
tients preferred and would not change the present anti-TNF-α therapy, how-
ever, subcutaneous administration was preferred among those patients who 
had have experience with both. 
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1. Introduction 
Inflammatory bowel disease (IBD) is a chronic inflammatory intestinal disorder 
defined clinically into two major entities: Crohn’s disease (CD) and ulcerative 
colitis (UC). These diseases can affect the entire gastrointestinal tract [1]. While 
the exact etiopathogenesis of the disease remains unknown, it is widely accepted 
that both CD and UC originate from an inappropriate immune response in ge-
netically susceptible individuals as a result of complex interactions of genetic, 
environmental and microbial factors [2]. These conditions usually require a life-
long treatment because of the complex, uncertain and chronic nature of the dis-
ease. The goal of the treatment in the management of IBD is not only to achieve 
clinical improvement but also to alter the course of disease and to restore a 
normal bowel function. This requires the suppression of inflammation and the 
induction of complete mucosal healing [3] [4]. With the early use of biological 
agents, these treatment goals can now be achieved. Infliximab (IFX) and 
adalimumab (ADA) are the two firstly and most widely used anti-TNF-α bio-
logical therapies licensed for the treatment of IBD (CD and/or UC) in Europe. In 
1997, IFX was the first biological agent used for the treatment of moderate to 
severe CD in patients with inadequate response to corticosteroid and/or immu-
nosuppressant therapy, or who could not tolerate the side effects or had contra-
indications. Later IFX was subsequently used for the treatment of UC in similar 
indications. The recommended dose of IFX is 5 mg/kg given as an intravenous 
induction regimen at first, second and sixth week followed by a maintenance 
regimen of 5 mg/kg every eighth week. Patients have to spend time on treat-
ment, because of waiting for blood test and for IFX infusion therapy at outpa-
tient clinic. An infusion is given approximately over 2 hours, after that they have 
to stay for clinical observation in case of late infusion reactions occurred. ADA 
has been available in Hungary since 2007 and in contrast to IFX, and it is ad-
ministered as a subcutaneous injection usually every other week, at dose of 160 
mg, 80 mg for induction and subsequently 40 mg every other week for mainte-
nance. This subcutaneous injection can be administered by general practitioner, 
nurse or by the patient after learning self-injection technique. Self-administration 
requires high cooperation and compliance from patients. Clinical indications of 
these two anti-TNF agents are similar.  
On several occasions during IBD therapy can patient and doctor make deci-
sions, but how they decide? The decision about which one of the two anti-TNF 
agents receive the patient depends on the specialist’s recommendation and the 
patient’s preference. Allen PB et al. found a trend towards patient preference for 
IFX (iv.) treatment as opposed to ADA (sc.) [5]. They found the difference may 
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be due to the frequency of administration, mode of administration or differing 
‘times in the market-place’ [5]. Contrary Vavricka et al. found that patients pre-
ferred anti-TNF medications that were administered by subcutaneous injection 
rather than by intravenous infusion [6]. The two major factors influencing pa-
tient’s decision were the ease of use and the time required for therapy [6]. The 
aim of this study was to evaluate and compare the patients’ opinion and satisfac-
tion with the two types of anti-TNF-α therapies a Hungarian cohort of IBD pa-
tients.  
2. Materials and Methods 
This was a prospective, multicentre, questionnaire-based observational study 
carried out in three Hungarian tertiary centres. Adult patients diagnosed with 
UC or CD, who have administered at the time of the study or previously one 
or both of the two anti-TNF agents and performed anonymously question-
naire- based survey between April 2014 and September 2014, were enrolled in 
the study (Appendix 1). Patients who did not meet the above-mentioned in-
clusion criteria were excluded. The questionnaire contained questions for pa-
tient’s demographic data (gender, age, smoking history and patients’ highest 
educational level), IBD characteristics (year of diagnosis, disease phenotype, 
disease location, IBD related operations, concomitant medications), and fur-
ther questions were about patients’ preferences for anti-TNF drugs. Specifi-
cally, patients were asked about current and/or previous biological therapy, 
and the satisfaction in accordance with the current anti-TNF-α therapy. If they 
changed therapy, the reason and the satisfaction with previous or current 
therapy was also asked. Questions were about the price supposed of the bio-
logical agent they received, when and from who they heard first about biologi-
cal treatment, their worst experience during biological therapy, the side effects 
they noticed and whether they were anxious of biological therapy. Further 
questions were about the time after they felt improvement of their symptoms, 
if they have ever observed that the efficacy of biological therapy decreased be-
fore the next maintenance therapy. Further questions were: “Which biological 
agent would you prefer based on your experience if you can choose”; “What 
was the most effective therapy you have ever received”; “Have you been oper-
ated during biological therapy?”. Finally, patients were asked if they would 
participate in a new drug trial even though they would have to stop their cur-
rent biological treatment or not.  
Statistics 
The collected data were analysed statistically. Data were analysed using Pear-
son’s chi-square test, and Fisher exact test. P < 0.05 was considered statistically 
significant. For the statistical analysis, R statistical program (version 3.2.5) was 
used. 
Ethical approval 
The study was approved by the Regional and Institutional Human Medical 
Biological Research Ethics Committee of the University of Szeged. 





Two hundred and ninety-two IBD patients (133 women, 159 men, mean age 
35 (15 - 67) years) were prospectively enrolled. Table 1 gives an overview of the  
 
Table 1. Baseline Characteristics of Patients. 
Item Frequency 
Number of patients 292 
Females/males 133/159 
Age (years; mean ± SD) 35 ± 11.4, range 15 - 67 
CD/UC/not determined 216/75/1 
Crohn’s disease location  
 L1 ileum 13% 
 L2 colon 31% 
 L3 ileocolonic 49.5% 
 not responded 6.5% 
Crohn’s disease, disease duration (yrs)  
 <1 year 0% 
 1 - 5 years 32.4% 
 >5 years 65.3% 
 not responded 2.3% 
UC patients disease extent  
 proctitis 16.2% 
 left sided colitis 29.7% 
 pancolitis 55.4% 
 not responded 2.7% 
Ulcerative colitis, disease duration (yrs)  
 <1 year 0% 
 1 - 5 years 34.7% 
 >5 years 65.3% 
Active smokers  
 CD 17% 
 UC 10.7% 
Educational level  
 No education 0% 
 Elementary school 7.2% 
 High school 46.9% 
 Apprenticeship and college program 31.5% 
 University degree 11.3% 
 Not responded 3.1% 
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patient characteristics. Disease phenotype was determined in accordance with 
Montreal Classification [7]. The mean disease duration was 9.32 ± 6.63 years in 
CD patients and 11 ± 7.92 years in UC patients. The majority of patients 
(141/216, 65.3% of CD patients, 49/75, 65.3% of UC patients) have long-standing 
disease (disease duration > 5 years). 141 of 292, 48.3% of patients were non- 
smoker (93/216, 43.1% of CD patients; 48/75, 64% of UC patients), 100 of 292, 
34.2% were ex-smoker, 45 of 292, 15.4% were current smoker, while 6 of 292, 
2.1% of patients have not responded. One hundred and twenty patients have 
ever required IBD related surgical intervention in an average 2.87, (1 - 12) times. 
IBD-related medication  
259 patients have received one of the biological treatments at the time of the 
survey. 153 were receiving IFX and 106 ADA. At the time of the survey 33 pa-
tients have already finished their biological therapy. 137 of 259, 52.9% of those 
patients who have received one of the biological therapies at the time of the sur-
vey were on concomitant medications (5-aminosalicylates: 25/137, 18.2%; ster-
oids: 16/137, 11.7%; thiopurine: 41/137, 30%; antibiotics: 4/137, 2.6%; not re-
sponded: 77/137, 56.2%). The mean duration of biological therapy was 1.7 years 
(in range 1 - 7 years). The majority of the patients have received only IFX cur-
rently or previously (168/292, 57.5%); 79 of 292, 27% of the patients have had 
experience with both anti-TNF agents, majority of them (68/79, 86%) switched 
from IFX to ADA, while only 45 of 79, 15.4% of the patients received only ADA 
(currently or previously). The main reason of switching anti-TNF agents men-
tioned by the patients was lack of efficacy (31/79, 39%), allergy (25/79, 31%) and 
other complications like arthralgia or thrombocytopenia.  
Patients Satisfaction with Biological Therapy 
The majority of the patients (259/292, 88%) treated with biological therapy 
were satisfied with their management (138/153, 90% of IFX; 90/106, 84% of 
ADA treated patients). 33 of 292, 12% of the patients were unsatisfied with their 
therapy, they mentioned lack of efficacy, side effects (joint and bone pain), and 6 
of them did not answer to the question. 79 patients had experiences with both 
biological agent, majority of them (33/79, 42%) was more satisfied with ADA 
treatment, they mentioned that ADA is more effective, they were satisfied with 
the ease of use and less side effect of ADA. 15 of 79, 19% of the patients was 
content with IFX because of its effectiveness. According to the patients’ decision 
biological therapy was the most effective treatment ever. 181 of 292, 62% of them 
found biological therapy the most effective therapy ever received. Other treat-
ment like steroid (32/292, 11%), thiopurine (15/292, 5.1%) was also found effec-
tive. Important to note, that 70 of 292, 24% of the patients did not fulfil this 
question.  
Patients treated with IFX felt the effectiveness of the therapy at first time be-
tween the 4-5th week, while patients on ADA therapy felt it between the 5-6th 
week. More than half of the patients felt ever loss of effectiveness before the next 
regular infusion/injection. 268 patients replied on this question, 168 received 
IFX, 100 received ADA. Almost 60% (102/168) of those patients who were on 
Á. Milassin et al. 
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IFX marked feeling loss of effectiveness, while on ADA that percentage was 51% 
(51/100).  
Do patients want to switch therapy?  
We asked from the patients: “If you could choose from biological treatments, 
which would you choose?”. 116 of 292, 39.7% of the patients chose IFX, 85 of 
292, 29.5% chose ADA, 2 of 292, 0.65% chose both and 2 of 292, 0.65% chose 
none of the biological agents. 87 of 292, 29.5% of the patients did not respond to 
the question. 100 of 168 IFX treated patients (note, that 63 not responded) 
would choose IFX again and they mentioned: “This treatment is effective for 
me”; “I have no experiences with other biological therapy”; ” I prefer to take 
drug less often”; “I don’t like the idea of self-injecting”; “fewer side effects”; 
“medical supervision during infusion”. 29 of 45 only ADA treated patients (note 
that 15 not responded) would choose ADA again and they mentioned: “This 
treatment is effective for me”, “I have no other experiences with other biological 
agents”; “It is more comfortable for me to give the injection at home”. The rea-
sons cited for those patients who had experience with both anti-TNF-α agents 
and chose IFX (and the latest biological therapy was IFX), were: “This is more 
effective and I can feel the effect quicker than other biological agent” (n = 12), “I 
prefer to take drug less often” (n = 1). Significantly (p = 0.007) more from those 
patients, who had experiences with both anti-TNF-α agents and the latest bio-
logical therapy was ADA, chose ADA, and the reasons mentioned were: “I prefer 
the convenience of self-injecting at home and I don’t have to wait so much.” (n = 
17), “This treatment is effective for me” (n = 15), fewer side effects (n = 10). 
From them who chose IFX they mentioned “IFX was more effective” and they 
liked the infusion’s frequency.  
Mode of administration 
Questions were about the patients’ current treatment and about the mode of 
administration. In case of the current treatment was IFX (n = 179), the majority 
of the patients were satisfied with the infusion’s time, and length of the therapy 
(150/179, 84%), while the mode of administration did not disturb them (163/ 
179, 91%). They were asked whether they prefer the administration of IFX sub-
cutaneously, like ADA, and 127 of 179, 71% were satisfied with the current in-
travenous mode of administration. In case of the current treatment was ADA (n 
= 113), the majority of the patients were satisfied with the subcutaneous mode of 
administration and with the therapy’s frequency and did not disturb them (101 
of 113, 89% - 89%). Who gives the subcutaneous injection was also asked: the 
majority of the patients give the injection themselves (76/113, 67%), in other 
cases the injection is given by a family member or general practitioner (16/113, 
14%; 14/113, 12%). The majority of the patients were satisfied with the mode of 
administration and they would not change it. There was no difference between 
the patients’ satisfaction regarding the type of anti TNF-α therapy if they re-
ceived both. However, subcutaneous administration was preferred by ADA- 
treated patients, previously receiving IFX (p = 0.007) compared to intravenous 
route and they do not intend to change the mode of administration of the ther-
Á. Milassin et al. 
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apy (p = 0.043).  
Side effects and fears of biological therapy 
Seventy-two patients (from 267 respondents) noticed side effect of biological 
therapy during their treatment period, 57 patients were on IFX, and 10 were on 
ADA, while 1 patient experienced side effect with both anti-TNF α therapy. 195 
of 267, 73% of respondents haven’t mentioned any side effect during biological 
therapy. Allergic or infusion reaction was mentioned by 27 patients (26 of 27, 
96% was on IFX, 1 of 27, 4% was on ADA), such as breathlessness, and angiooe-
dema. Skin problems were occurred in 15 patients (12 were on IFX, 2 were on 
ADA, 1 was on both anti-TNF α agents) such as skin rash, itchy skin, dry skin, 
and skin sensitivity. Joint and/or muscle complaints or pain was mentioned by 
13 patients (8 patients were on IFX, 3 patients were on ADA). Infections (Herpes 
Simplex Virus, Human Papilloma Virus, Mycobacterium tuberculosis, flu-like 
infection) occurred in 9 cases. 10 cases appeared tiredness, depression, headache, 
nausea, hair loss. Regarding adverse events there was no significant differences 
between ADA and IFX according to patients’ opinion.  
In the majority of the cases (112/182, 61.5%), patients did not mention any 
complaints with biological therapy. The rest of the patients had complaints 
about the time for waiting for the infusion and travelling to the Hospital (45/182, 
24.7%), the side effects (8/182, 4.4%), the efficacy of the treatment (8/182, 4.4%), 
the administration of medicaments (fear from the sting of a needle, collapsed 
veins, pain from subcutaneous injection) and cooling the injection during travel-
ling (9/182, 5%). 
Patients mentioned adverse events (29/228, 12.7%), problems with admini-
stration (21/228, 9.2%), relapse of the disease (8/228, 3.5%) and the time for 
waiting (6/228, 2.6%) as the worst experience during the biological therapy. 
According to our survey 63 of 291 patients, 21.65% were anxious because of 
the biological therapy; adverse events may occur during treatment (n = 32), long 
term effects are unknown (n = 18), malignancies may develop (n = 2), infections 
can occur (n = 2), treatment can affect pregnancy (n = 1) were mentioned. 
Patients’ knowledge about anti-TNF drugs 
Most of the patients collect information about their accurate medical therapy 
from their physician (232/292, 79.4%). Getting information from internet (14/ 
292, 4.8%), asking other patients or visiting patients forum (11/292, 3.7%), 
friends (8/292, 2.7%), school (1/292, 0.4%) or television (1/292, 0.4%) were less 
frequently. Note, that 25 of 292, 8.6% of the patients quitted this question.  
Patients were also asked about what they think about one therapies price. The 
mean price of IFX was supposed to be approximately 635,000 HUF, while the of-
ficial price was approximately 153,000 HUF. The mean price of ADA was sup-
posed to be approximately 446,000 HUF, while the official price was approxi-
mately 275,000 HUF at the time of the survey.  
4. Discussion 
In this prospective, multicentre observational study of the IBD patients’ opinion 
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and satisfaction about the currently available two anti-TNF drugs in Hungary 
were evaluated and a questionnaire based survey was used. Questionnaires were 
distributed between April 2014 and September 2014 among adult patients diag-
nosed with UC or CD and received separately IFX, ADA or both IFX and ADA 
after each other. Two-thirds of the patients included in the survey were on IFX 
therapy at the time of the study and 27% of the patients have been treated with 
both anti TNF agents.  
Generally we found no significant differences in the patients’ preferences for 
choosing one of the anti-TNF drugs (IFX or ADA). Our results showed that pa-
tients were satisfied with their current anti-TNF therapy; they found them effec-
tive therefore they did not want to change it to other anti-TNF medication with 
uncertain effect on their symptoms. Regarding those patients who were treated 
with both anti-TNF drugs, we found a tendency in preferring the currently used 
anti-TNF drugs. We found a tendency towards ADA treated patients like subcu-
taneous administration and they did not show a tendency to change it, while pa-
tients on IFX therapy, who were discontent with their therapy showed a ten-
dency to change it to subcutaneous administration, and the time required for 
administration of IFX infusion was the main reason mentioned.  
The majority of patients with IBD require long-term medication for disease 
control and maintenance of remission. Only limited data are available on the pa-
tients’ knowledge and preference on biological therapy, although better cogni-
tion of the patients’ opinion would improve the adherence to medications. Pa-
tient preference studies for anti TNF therapies are usually from the field of 
rheumatology. In rheumatoid arthritis studies, most patients prefer ADA to IFX 
because of the more convenient administration route of the drug [8] [9]. The 
main differences between IFX and ADA are the route of administration (hospital 
vs. self administered infusion/injection), frequency of dosing and the time on 
market. Although IFX has been licensed for a greater time on the market than 
ADA, both drugs have been used for years and proved their efficacy in the 
treatment of IBD. Frequency of dosing and route of administration are poten-
tially modifiable factors of nonadherence to maintenance medication for IBD 
which occurs in 30% - 45% of patients [10] [11]. Therefore adequately informing 
patients and considering their preference is important to improve adherence to 
therapy. The study by Selinger et al. revealed that patients on IFX were more 
adherent, than patients on ADA [11].  
Several studies found that one anti-TNF drug is more preferred than other, 
but the results were controversial. Contrary to our data, in the study by Allen et 
al. nearly twice the number of patients chose IFX over ADA because of the lower 
frequency of dosing in 42% of the cases. The commonest reason cited for those 
who chose IFX (67%) was that they did not like ‘self-injecting administration’ 
[5]. However, the study was not powered enough to draw significant conclusions 
and this difference did not reach statistical significance as well. In accordance 
with our results, they could not reveal any difference in preference for either an-
ti-TNF therapy. Vavricka et al. evaluated the preferences of anti TNF naive CD 
Á. Milassin et al. 
 
1015 
patients for selecting one of the anti TNF drugs. Most patients preferred ADA 
and certolizumab pegol to IFX because of the ease of their subcutaneous ad-
ministration and the reduced amount of time required to receive the therapy in 
comparison to anti-TNF drugs delivered by intravenous route [6]. Our findings 
on patient preferences for subcutaneous administration are comparable to pref-
erences of rheumatoid arthritis patients and CD patients in the Vavricka study. 
However an important difference between our and Vavricka’s study was that we 
included anti TNF experienced patients treated with either or both anti TNF 
drugs. Among patients who were treated with both agents, ADA was more pre-
ferred compared to IFX: patients found ADA to be more effective and they were 
satisfied with the ease of use and less side effects of the drug. Notably, patients 
treated with both agents were switched from IFX to ADA in 86% of the cases 
and the main reason of switching anti-TNF agents were loss of response and in-
fusion reactions occurred during IFX therapy [6].  
We found a tendency that patients treated with IFX felt the effectiveness of 
therapy earlier than patients treated with ADA but there were no significant dif-
ferences between the two groups.  
The limitation of the study was the relatively low response rates of certain 
parts of the survey despite the high number of enrolled patients. However, the 
study was able to demonstrate that the majority of the patients on biological 
therapy were satisfied with their management and found anti TNF therapy the 
most effective ever received. The majority of the patients received medical in-
formation from their physician suggesting an accurate knowledge about the 
therapies. 60% of IFX and 64% of ADA treated patients would choose their 
therapy again because they found them effective and do not have experience 
with the other agent. However, interviewed patients who preferred IFX stated 
that “I prefer to take drug less often” and “I don’t like the idea of self-injecting” 
that determined the choice of therapy. The patients preferring ADA identified 
the comfortable route of giving the injection at home as a factor influencing 
their treatment choice.  
Route and frequency of drug administration and side effects may play role in 
decision making of IBD patients. According to our results Hungarian IBD pa-
tients prefer subcutaneous administration because of its convenience and time 
saving property, but they also find both IFX and ADA effective. Our result sug-
gest that beside the route of administration and the therapy’s effect the key fac-
tors influencing a decision to choose a therapy for patients were physician’s 
recommendation. Further studies are required in IBD patients to investigate 
whether patients’ decision affect their compliance, satisfaction and effectiveness 
of anti-TNF therapies. 
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Appendix 1. Questionnaire on Patients Preferences  
Regarding Biological Therapy 
Questionnaire on patients’ preferences regarding biological therapy 
1. Gender (male/female):  
2. Type of IBD disease (Crohn’s disease/ulcerative colitis):  
3. Age:  
4. Year of diagnosis:  
5/a Localisation of Crohn’s disease (small intestine, large intestine, both): 
5/b Extension of ulcerative colitis (proctitis/left sided/pancolitis): 
7. Current smoking history (never/yes, before/yes, currently):  
8. Highest degree of education:  
9. Have You ever been operated due to IBD? 
  If yes, how many times?  
  What kind of operations did You have?  
10. Do You receive currently biological treatment? 
  If yes, which anti-TNF-alfa medication do You receive?  
11. Have You ever received before biological treatment? 
If yes, which anti-TNF-alfa medication have You received? 
If yes, how many 1 year period have you received?  
12. Was it needed to change biological treatment during biological therapy? 
  If yes, from which to which? 
  If yes, why was the therapy changed (loss of efficacy/allergy/other)? 
13. Are you satisfied with your current therapy?  
  If no, why not?  
14. If biological therapy was changed, which were you more satisfied with?  
Why? 
15. What do you think how expensive one biological treatment?  
In case of Remicade? 
In case of Humira? 
16. When and from who did you hear at first time about the biological ther-
apy?  
17. What is your biggest problem with your biological treatment? 
18. If you are on Remicade therapy,  
the length of the therapy disturb you? 
  the intravenous regimen disturb you? 
would you prefer subcutaneous injection, but every second week?  
19. If you are on Humira therapy, 
  do You give injection yourself? If no, who helps you? 
  are You satisfied with subcutaneous injection?  
every week or every second week injection disturb you? 
would you prefer every 8th week administer biological therapy, but in-
travenously?  
20. Do you have any fear of biological therapy?  
  If yes, why? 
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21. How do you remember, in which week did you feel the therapy’s effect? 
22. Did you feel any symptoms which meant you that before the next infusion 
/injection the therapy’s effect decreased?  
23. What was your worst experience during the biological treatment?  
24. Did you experience any side effect of therapy?  
If yes, with which therapy? 
What kind of side effects did you experience? 
25. If you would have the choice to choose biological therapy now, which 
would you choose?  
  Why?  
26. From who/where do you get information about biological therapy? (physi-
cian, internet, friend, books, other)? 
27. In the last year how many times did you visit your gastroenterologist phy-
sician because of biological therapy?  
28. What kind of other therapy do you take regularly because of Your IBD?  
29. Until now, which therapy was the most effective? You can choose any of 
your medication.  
30. Have you been operated from the start of the biological therapy?  
  If yes, on which treatment were you at the time of the operation?  
31. Would you like to participate in a new study drug trying, if your current 
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